Sunovion Pharmaceuticals Inc.
84 Waterford Drive
About Sunovion Pharmaceuticals Inc.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. Our vision is to lead the way to a healthier world, and we believe scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything we do, we have charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
295 articles with Sunovion Pharmaceuticals Inc.
Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
SEP-363856 was identified through a collaboration between Sunovion and PsychoGenics
AstraZeneca is unloading rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis. The company indicates that the rights cover markets outside the United States and the U.S. royalties for the drugs.
Kedalion Therapeutics, Inc. today announced the hiring of medical device industry veteran Reynaldo Quintana as Vice President of Engineering.
Sunovion Announces Health Canada Approval of Aptiom® (eslicarbazepine acetate) as Adjunctive Therapy for the Treatment of Partial-Onset Seizures in Adolescents and Children Above Six Years of Age
APTIOM provides an important new treatment option for adolescents and children above six years of age with partial-onset seizures
Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
Study met its primary endpoint demonstrating fewer binge days per week with dasotraline versus placebo in the treatment of adults with moderate to severe binge eating disorder.
Sunovion to Launch Take On Tomorrow™ Giving Opportunity with Red Sox Foundation and 7th Annual Community Service Program
Expecting to Reach 25,000 Cumulative Employee Volunteer Hours This Summer, Company Will Mark Milestone by Donating $25,000 to Support Education and Mental Health Initiatives
As Treatments Await FDA Ruling, Researchers Discover ‘Key Players’ in Early-Onset Parkinson’s Dis...
6/15/2018While pharma and biotech researchers have been driving forward with therapies aimed at helping Parkinson’s disease patients, medical researchers have identified “unexpected new key players” in the development of early-onset Parkinson’s disease, called Parkinsonism.
Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for apomorphine sublingual film (APL-130277)
Approximately 25 percent of adults in the United States will deal with some form of mental illness within a given year. It’s also estimated that many of the people who experience these problems may never report it or seek help.
Sunovion to Deliver Multiple Presentations at the 2018 American Psychiatric Association Annual Meeting
– New data analyses highlight the use of Latuda® (lurasidone HCl) in pediatric populations, including long-term efficacy and safety outcomes in bipolar depression and schizophrenia – – Further data on use of dasotraline in children and adults with ADHD and adults with binge eating disorder (BED) will be presented –
Sunovion Announces Lonhala™ Magnair™ (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD
LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) available for the treatment of COPD in the U.S.
Sunovion Pharmaceuticals announced it submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for apomorphine sublingual film to treat OFF episodes in Parkinson’s disease (PD).
Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film (APL-130277) for the Treatment of OFF Episodes Associated with Parkinson’s Disease
Submission is supported by Phase 3 clinical study data showing that the investigational medicine demonstrated superior efficacy versus placebo for the on-demand treatment of OFF episodes associated with Parkinson’s disease.
3/6/2018There is a newly approved treatment for pediatric patients with major depressing episodes associated with bipolar disorder.
Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda® (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) that expands the use of Latuda® (lurasidone HCI) to include the treatment of major depressive episode associated with bipolar I disorder (bipolar depression) in pediatric patients (10 to 17 years of age).
The drug met its primary and key secondary endpoints, and the medicine was also generally well-tolerated by study participants.
Magnair an eFlow Closed System Nebulizer Together With Sunovion's Lonhala is the First eFlow Technology Based Product to Receive FDA Approval to Treat COPD
The drug//device combination product received FDA approval on December 5th, 2017 under a NDA.
Sunovion expects LONHALA MAGNAIR to be available in U.S. pharmacies in early 2018.
Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Trea...
11/10/2017The NDA submission is supported by multiple placebo-controlled safety and efficacy studies, as well as two long-term studies that assessed the safety of dasotraline in people with ADHD for up to one year.
Sunovion Presents New Phase 3 Study Analyses Supporting Safety and Efficacy of SUN-101/eFlow (Glycopyrrolate) for the Treatment of COPD
Sunovion Pharmaceuticals today presented new secondary analyses of safety and efficacy data from the Phase 3 GOLDEN clinical study program for SUN-101/eFlow (glycopyrrolate) at the American College of Chest Physicians (CHEST) Annual Meeting 2017 held October 28-November 1, 2017, in Toronto, Canada.